Previous studies show that baseline use of GC (≥10 mg of prednisone equivalent daily) or early use of GC (<2 months after starting immunotherapy) are associated with decreased ORR, PFS, and OS in NSCLC and other solid cancers administrated with PD-1/PD-L1 blockers (18–21, 33). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.